About Renalys
Renalys is a company based in Chuo (Japan) founded in 2023 by Takeshi Takahashi and BT Slingsby was acquired by Chugai Pharmaceutical in October 2025. Renalys has raised $38.2 million across 1 funding round from investors including Chugai Pharmaceutical, Catalys Pacific and SR One. Renalys operates in a competitive market with competitors including Calliditas Therapeutics, Enyo Pharma, Unicycive, Akebia Therapeutics and Alebund, among others.
- Headquarter Chuo, Japan
- Founders Takeshi Takahashi, BT Slingsby
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$38.2 M (USD)
in 1 rounds
-
Latest Funding Round
$38.2 M (USD), Series A
Jul 17, 2024
-
Investors
Chugai Pharmaceutical
& 6 more
-
Employee Count
Not available
-
Acquired by
Chugai Pharmaceutical
(Oct 24, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Renalys
Renalys has successfully raised a total of $38.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $38.2 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Renalys
Renalys has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Chugai Pharmaceutical, Catalys Pacific and SR One.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A biotechnology venture capital firm investing in innovative science.
|
Locked | Locked | Locked | |
|
VC firm investing in Japan and the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Renalys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Renalys
Investment portfolio details for Renalys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Renalys
Detailed financials for Renalys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Renalys Comparisons
Peer comparison for Renalys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Renalys
Renalys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Enyo Pharma, Unicycive, Akebia Therapeutics and Alebund, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Therapeutics are developed for diseases with impaired kidney function.
|
|
| Locked | Locked | Locked |
Small molecule therapies for kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| Locked | Locked | Locked |
Therapeutics for various kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
Detailed competitors of Renalys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Renalys
Complete news archive for Renalys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renalys
Renalys was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Renalys is headquartered in Chuo, Japan. It is registered at Chuo, Yamanashi Prefecture, Japan.
BT Slingsby is the current CEO of Renalys. They have also founded this company.
Renalys is a funded company, having raised a total of $38.2M across 1 funding round to date.
Renalys was established in 2023 in Chuo City, Japan, within the biotechnology sector. Focus is placed on developing therapeutics for renal diseases. Sparsentan, an oral dual endothelin angiotensin receptor antagonist, has been introduced for treating IgA nephropathy. Operations center on advancing treatments for kidney-related conditions, with co-founders Takeshi Takahashi and BT Slingsby leading efforts in this specialized field.
Renalys's top competitors include Calliditas Therapeutics, Enyo Pharma and Akebia Therapeutics.
Renalys has 7 investors. Key investors include Chugai Pharmaceutical, Catalys Pacific, SR One, JP Investment, and Sumitomo Mitsui Trust Bank.